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GidB mutation as a phylogenetic marker for Q1 cluster Mycobacterium tuberculosis isolates
and intermediate-level streptomycin resistance determinant in Lisbon, Portugal
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Abstract
Development of streptomycin resistance in Mycobacterium tuberculosis is usually associated with mutations in rpsL and rrs genes, although up
to 50% of clinical streptomycin-resistant isolates may present no mutation in either of these genes. In the present report we investigate the
role of gidB gene mutations in streptomycin resistance. We have analyzed 52 streptomycin-resistant and 30 streptomycin-susceptible
Mycobacterium tuberculosis clinical isolates by sequencing and endonuclease analysis of the gidB and rpsL genes. All clinical isolates were
genotyped by 12-loci MIRU-VNTR. The gidB gene of 18 streptomycin-resistant isolates was sequenced and four missense mutations were
found: F12L (1/18), L16R (18/18), A80P (4/18) and S100F (18/18). The remaining isolates were screened by endonuclease analysis for
mutations A80P in the gidB gene and K43R in the rpsL gene. Overall, mutation A80P in the gidB gene was found in eight streptomycin-
resistant isolates and 11 streptomycin-susceptible multidrug-resistant isolates. Also noteworthy, is the fact that gidB mutations were only
present in isolates without rpsL and rrs mutations, all from genetic cluster Q1. Streptomycin quantitative drug susceptibility testing showed
that isolates carrying the gidB A80P mutation were streptomycin intermediate-level resistant and that standard drug susceptibility testing
yielded inconsistent results, probably due to borderline resistance. We conclude that gidB mutations may explain the high number of
streptomycin-resistant strains with no mutation in rpsL or rrs. These mutations might occasionally confer low-level streptomycin resistance
that will go undetected in standard susceptibility testing.
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Abstract
Staphylococcus aureus is the most commonly isolated pathogen in respiratory tract secretions from young patients with cystic ﬁbrosis (CF),
and several treatment strategies are used to control the infection. However, it is not known whether intensiﬁed treatment with
antimicrobial agents causes eradication of S. aureus clones. We retrospectively determined the impact of intravenous (IV) antimicrobial
agents on the suppression and eradication of S. aureus clones. One thousand and sixty-one S. aureus isolates cultured from 2526 samples
from 130 CF patients during a 2-year study period were subjected to spa typing. Intervals between positive samples and the occurrence of
clone replacements were calculated in relation to courses of IV antimicrobial agents. Of 65 patients chronically infected with S. aureus, 37
received 139 courses of IV antimicrobial agents with activity against S. aureus (mean duration, 15 days; range, 6–31 days). Administration of
IV antibiotics increased the time to the next sample with growth of S. aureus: the mean interval between two positive samples was 68 days if
IV treatment had been administered, in contrast to 49 days if no IV treatment had been administered (p 0.003). When S. aureus recurred in
sputum after IV treatment, the isolate belonged to a different clone in 33 of 114 (29%) intervals, in comparison with 68 of 232 (29%)
intervals where IV treatment had not been prescribed (OR 0.98, 95% CI 0.60–1.61). In conclusion, we show that 2 weeks of IV
antimicrobial treatment can signiﬁcantly suppress chronic staphylococcal infection in CF, but is not associated with the eradication of
persistent bacterial clones.
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